AbbVie reported a robust Q1 2026 with net revenue up 12.4% year-over-year, fueled by strong sales in Immunology drugs Skyrizi (+29%) and Rinvoq (+20%), as well as a 24% increase in Neuroscience products. The company raised its 2026 earnings per share guidance to $14.18, indicating a 42% growth from the previous year. With a solid pipeline, diversified growth drivers, a 3.4% dividend yield, and a strong balance sheet, AbbVie is rated a 'Buy' for investors seeking both income and growth. This outlook reflects confidence in AbbVie's ability to sustain momentum and deliver shareholder value.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
